Romulo Pereira De Moura Sousa, Daniele de Figuerêdo Silva, Neuza Maria Cavalcante Oliveira, Zélia Braz Vieira Da Silva Pontes, Hermes Diniz Neto, Laísa Vilar Cordeiro, Pedro Thiago Ramalho de Figueiredo, Rafael Farias de Oliveira, Helivaldo Diógenes da Silva Souza, P. de Athayde Filho, E. de Oliveira Lima
{"title":"In silico and in vitro analysis of a new potential antifungal substance, 2-Bromo-Nphenylacetamide, against invasive candidiasis isolates","authors":"Romulo Pereira De Moura Sousa, Daniele de Figuerêdo Silva, Neuza Maria Cavalcante Oliveira, Zélia Braz Vieira Da Silva Pontes, Hermes Diniz Neto, Laísa Vilar Cordeiro, Pedro Thiago Ramalho de Figueiredo, Rafael Farias de Oliveira, Helivaldo Diógenes da Silva Souza, P. de Athayde Filho, E. de Oliveira Lima","doi":"10.15446/rcciquifa.v50n3.100227","DOIUrl":null,"url":null,"abstract":"Introduction: invasive candidiasis is related to high rates of morbidity and mortality. There are few classes of drugs available for the treatment of this type of infection and the index of resistant strains is increasing. Such circumstances highlight that the search for new pharmacotherapeutic alternatives is increasingly necessary. This study investigated 2-Bromo-N-phenylacetamide, a substance whose antifungal activity has not yet been reported. Objective: to evaluate its activity against invasive candidiasis isolates, by determining the minimum inhibitory and fungicide concentrations. Meth-odology: molecular docking was performed to investigate the possible mechanism of action of the substance. The substance was also associated with fluconazole, to assess the viability of the combination in clinical practice. The minimum inhibitory concen-trations ranged between 4 to 32 μg/mL, and it acts in a fungicidal way. Results: molec-ular docking suggests that 2-Bromo-N-phenylacetamide possibly acts on the fungal plasma membrane. And the association of 2-Bromo-N-phenylacetamide with flucon-azole against resistant strains showed an indifferent effect. Conclusion: further studies should be carried out to elucidate the potential of this substance, which may become a future drug candidate to treat invasive candidiasis and other fungal infections.","PeriodicalId":21220,"journal":{"name":"Revista Colombiana de Ciencias Químico-Farmacéuticas","volume":"11 3 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista Colombiana de Ciencias Químico-Farmacéuticas","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15446/rcciquifa.v50n3.100227","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: invasive candidiasis is related to high rates of morbidity and mortality. There are few classes of drugs available for the treatment of this type of infection and the index of resistant strains is increasing. Such circumstances highlight that the search for new pharmacotherapeutic alternatives is increasingly necessary. This study investigated 2-Bromo-N-phenylacetamide, a substance whose antifungal activity has not yet been reported. Objective: to evaluate its activity against invasive candidiasis isolates, by determining the minimum inhibitory and fungicide concentrations. Meth-odology: molecular docking was performed to investigate the possible mechanism of action of the substance. The substance was also associated with fluconazole, to assess the viability of the combination in clinical practice. The minimum inhibitory concen-trations ranged between 4 to 32 μg/mL, and it acts in a fungicidal way. Results: molec-ular docking suggests that 2-Bromo-N-phenylacetamide possibly acts on the fungal plasma membrane. And the association of 2-Bromo-N-phenylacetamide with flucon-azole against resistant strains showed an indifferent effect. Conclusion: further studies should be carried out to elucidate the potential of this substance, which may become a future drug candidate to treat invasive candidiasis and other fungal infections.
简介:侵袭性念珠菌病与高发病率和死亡率有关。可用于治疗这类感染的药物种类很少,耐药菌株的指数正在增加。这种情况突出表明,寻找新的药物治疗方案是越来越必要的。本研究研究了2-溴- n -苯乙酰胺,一种抗真菌活性尚未报道的物质。目的:通过测定其最低抑菌浓度和杀菌剂浓度,评价其对侵袭性念珠菌分离株的抑菌活性。方法:进行分子对接,探讨该物质可能的作用机制。该物质还与氟康唑相关联,以评估该组合在临床实践中的可行性。最低抑菌浓度在4 ~ 32 μg/mL之间,具有一定的杀真菌作用。结果:分子对接提示2-溴- n -苯乙酰胺可能作用于真菌质膜。2-溴- n-苯乙酰胺与氟康唑联用对耐药菌株效果不显著。结论:该物质可能成为治疗侵袭性念珠菌病和其他真菌感染的候选药物,有待进一步研究。